Sequential therapy with tamoxifen and aromatase inhibitors in early-stage postmenopausal breast cancer: A review of the evidence

Oncology Nursing Forum

Volumn 35, Issue 4, 2008, Pages 714-721

  Litsas, Georgia ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

BONE DENSITY; BREAST TUMOR; CANCER STAGING; DRUG EFFECT; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; MORTALITY; NURSE ATTITUDE; NURSING ASSESSMENT; ONCOLOGY NURSING; PATHOLOGY; PATIENT EDUCATION; PATIENT SELECTION; PHYSIOLOGY; POSTMENOPAUSE; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BONE DENSITY; BREAST NEOPLASMS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; NEOPLASM STAGING; NURSE'S ROLE; NURSING ASSESSMENT; ONCOLOGIC NURSING; PATIENT EDUCATION AS TOPIC; PATIENT SELECTION; POSTMENOPAUSE; QUALITY OF LIFE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SURVIVAL RATE; TAMOXIFEN; TREATMENT OUTCOME;

EID: 53449086643     PISSN: 0190535X     EISSN: 15380688     Source Type: Journal    
DOI: 10.1188/08.ONF.714-721     Document Type: Article

References (71)

1. Ali, S., & Coombes, R.C. (2002). Endocrine-responsive breast cancer and strategies for combating resistance. Nature Reviews: Cancer, 2(2), 101-112.
2. American Cancer Society. (2008). Cancer facts and figures 2008. Atlanta, GA: Author.
3. American College of Obstetricians and Gynecologists. (1996). ACOG committee opinion. Tamoxifen and endometrial cancer. International Journal of Gynaecology and Obstetrics, 53(2), 197-199.
4. Arimidex, Tamoxifen, Alone or in Combination Trialists' Group. (2002). Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomized trial. Lancet, 359(9324), 2131-2139.
5. AstraZeneca Pharmaceuticals. (2007a). Arimidex® (anastrozole tablets) [Package insert]. Wilmington. DE: Author.
6. AstraZeneca Pharmaceuticals. (2007b). Nolvadex® (tamoxifen citrate tabids) [Package insert]. Wilmington, DE: Author.
7. Atalay, C., Dirix, L., Biganzoli, L., Beex, L., Nooij, M., Cameron, D., et al. (2004). The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: A companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients.' Annals of Oncology, 15(2), 211-217.
8. Boccardo, F.M., Rubagotti, A., Puntoni, M., Guglielmini, P., Porpiglia, M., Mesiti, M., el al. (2005). Switching to anastrozole (ANA) vs continued tamoxifen (TAM) treatment of early breast cancer (EBC). Updated results of the Italian Tamoxifen Anastrozole (ITA) trial. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings, 23(16S), 526.
9. Bria, E., Ciccarese, M., Giannarelli, D., Cuppone, F., Nistico, C., Nuzzo, C., et al. (2006). Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: Pooled-analysis of 8794 patients. Cancer Treatment Reviews, 32(5), 325-332.
10. Brueggemeier, R.W. (2002). Overview of the pharmacology of the aromatase inactivator exemestane. Breast Cancer Research and Treatment, 74(2), 177-185.
11. Brueggemeier, R.W., Hackett, J.C., & Diaz-Cruz, E.S. (2005). Aromatase inhibitors in the treatment of breast cancer. Endocrine Reviews, 26(3), 331-345.
12. Brufsky, A., Harker, C., Beck, Z., Carroll, R., Tan-Chiu, E., Seidler, C., et al. (2004. December 8-11). Zoledronic acid (ZA) for prevention of cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant Letrozole (Let): Preliminary results of the Z-FAST trial. Presented at the 27th Annual San Antonio Breast Cancer Symposium, San Antonio, TX.
13. Burstein, H.J., Mayer, E., Partridge, A.H., O'Kane, H., Litsas, G., Come, S.E., et al. (2006). Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: Cases and lessons. Clinical Breast Cancer. 7(2), 158-161.
14. Campos, S.M. (2004). Aromatase inhibitors for breast cancer in postmenopausal women. Oncologist, 9(2), 126-136.
15. Cella, D., Fallowfield, L., Barker, P., Cuzick, J., Locker, C., & Howell, A. (2006). Quality of life of postmenopausal women in the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Research and Treatment, 100(3), 273-284.
16. Coleman, R., Banks, L., Girgis, S., Vrdoljak, E., Fox, J., Porter, L., et al. (2005). Skeletal effect of exemestane in the Intergroup Exemestane Study (IES) 2 year bone mineral density (BMD) and bone biomarker data [Abstract 5076]. Breast Cancer Research and Treatment, 94(Suppl. 1), S233.
17. Coombes, R.C. Hall, E., Gibson, L.J., Paridaens, R., Jassem, J., Delozier, T., et al. (2004). A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. New England Journal of Medicine, 350(11), 1081-1092.
18. Coombes, R.C., Kilburn, L., Snowdon, C., Paridaens, R., Coleman, R., Jones, S., et al. (2007). Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial. Lancet, 369(9561), 559-570.
19. Coombes, R.C., Paridaens, R., Jassem, J., Van de Velde, C.J., Delozier, T. Jones, S.E., et al. (2006). First mature analysis of the Intergroup Exemestane Study [Abstract LBA527]. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I, 24(Suppl. 18).
20. Crew, K.D., Greenlee, H., Capodice, J., Raptis, C., Brafman, L., Fuentes, D., et al. (2007). Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. Journal of Clinical Oncology, 25(25), 3877-3883.
21. D'Hondt, V., & Piccart, M. (2004). Controversies in the adjuvant treatment of breast cancer: New adjuvant endocrine treatment strategies. Annals of Oncology, 15(Suppl. 4), 23-29.
22. Dixon, J.M. (2004). Exemestane and aromatase inhibitors in the management of advanced breast cancer. Expert Opinion on Pharmacotherapy, 5(2), 307-316.
23. Donnellan, P.P., Douglas, S.L., Cameron. D.A., & Leonard, R.C. (2001). Aromatase inhibitors and arthralgia. Journal of Clinical Oncology, 19(10), 2767.
24. Duggan, C. Murriot, K., Edwards, R., & Cuzick, J. (2003). Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. Journal of Clinical Oncology, 21(19), 3588-3593.
25. Early Breast Cancer Trialists' Collaborative Group. (1998). Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet, 351(9114), 1451-1467.
26. Early Breast Cancer Trialists' Collaborative Group. (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet, 365(9412), 1687-1717.
27. Eastell, R., Hannon, R.A., Cuzick, J., Dowsett, M., Clack, C., & Adams, J.E. (2006). Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole. Tamoxifen, Alone or in Combination (ATAC) trial (18233230). Journal of Bone and Mineral Research. 21(8), 1215-1223.
28. Fallowfield, L.J., Bliss, J.M., Porter, L.S., Price, M.H., Snowdon, C.F., Jones, S.E., et al. (2006). Quality of life in the Intergroup Exemestane Study: A randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. Journal of Clinical Oncology, 24(6), 910-917.
29. Fallowfield, L.J., Cella, D., Cuzick, J., Francis, S., Locker, C., & Howell, A. (2004). Quality of life of postmenopausal women in the Arimidex, Tamoxifen. Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. Journal of Clinical Oncology. 22(21), 4261-4271.
30. Fisher, B., Costantino, J.P., Wiekerham, D.L., Redmond, C.K., Kavanah, M., Cronin, W.M., et al. (1998). Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute, 90(18), 1371-1388.
31. Fisher, B., Dignam, J., Bryant, J., & Wolmark, N. (2001). Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. Journal of the National Cancer Institute, 93(9), 684-690.
32. Goldhirsch, A., Glick, J.H., Gelber, R.D., Coates, A.S., Thurlimann, B., & Senn, H.J. (2005). Meeting highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005. Annals of Oncology, 16(10), 1569-1583.
33. Goss, P.E. (2006). Preventing relapse beyond 5 years: The MA. 17 extended adjuvant trial. Seminars in Oncology, 33(2, Suppl. 7), S8-S12.
34. Goss, P.E., Ingle, J.N., Martino, S., Robert, N.J., Muss, H.B., Piccart, M.J., et al. (2003). A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. New England Journal of Medicine, 349(19), 1793-1802.
35. Goss, P.E., Ingle, J., Palmer, M., Shepherd, L., & Tu, D. (2005, December 8-11). Updated analysis of NCIC CTG MA.17 (lelmzole vs placebo to letmzole vs placebo) post unblinding. Presented at the 28th Annual San Antonio Breast Cancer Symposium, San Antonio. TX.
36. Gradishar, W.J. (2005). Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women. Oncology, 69(1), 1-9.
37. Grana, G. (2003). New developments in endocrine therapy: Role of adjuvant therapy for early breast cancer. Cancer Nursing, 26(Suppl. 6), 4S-9S.
38. Halkett, G., Arbon, P., Scutter, S., & Borg, M. (2006). The role of the breast care nurse during treatment for early breast cancer: The patient's perspective. Contemporary Nurse, 23(1), 46-57.
39. Harwood, K.V. (2004). Advances in endocrine therapy for breast cancer: Considering efficacy, safety, and quality of life. Clinical Journal of Oncology Nursing, 8(6), 629-637.
40. Hillner, B.E., Ingle, J.N., Chlebowski, R.T., Gralow, J., Yee, C.C. Janjan, N.A., et al. (2003). American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. Journal of Clinical Oncology, 21(21), 4042-4057.
41. Howell, A., Cuzick, J., Baum. M., Buzdar, A., Dowsett, M., Forbes, J.F., et al. (2005). Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet, 365(9453), 60-62.
42. Jakesz, R., Jonat, W., Gnant, M., Mittlboeck, M., Greil, R., Tausch, C., et al. (2005). Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet, 366(9484), 455-462.
43. Jansen, M.P., Foekens, J.A., van Staveren, I.L., Dirkzwager-Kiel, M.M., Ritstier, K., Look, M.P., et al. (2005). Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. Journal of Clinical Oncology, 23(4), 732-740.
44. Kaufmann, M., Jonat, W., Hilfrich, J., Eidmann, H., Gademann, G., Zuna. I., et al. (2006). Survival benefit of switching to anastrozole after 2 years' treatment with tamoxifen versus continued tamoxifen therapy: The ARNO 95 Study. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I., 24(18S, Suppl.), 547.
45. Kendall, A., Dowsett, M., Folkerd, E., & Smith, I. (2006). Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Annals of Oncology, 17(4), 584-587.
46. Lake, D.E., & Hudis. C. (2002). Aromatase inhibitors in breast cancer: An update. Cancer Control, 9(6), 490-498.
47. Lonning, P.E. (2002). The role of aromatase inactivators in the treatment of breast cancer. International Journal of Clinical Oncology, 7(4), 265-270.
48. Lonning, P.E. (2006). Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer. Annals of Oncology, 17(2), 217-225.
49. Lonning, P.E., Geisler, J., Krag, L.E., Erikstein, B., Bremnes, Y., Hagen, A.I., et al. (2005). Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. Journal of Clinical Oncology, 23(22), 5126-5137.
50. Lonning, P.E., Pfister, C., Martoni, A., & Zamagm, C. (2003). Pharmacokinetics of third-generation aromatase inhibitors. Seminars in Oncology, 30(4, Suppl. 14), 23-32.
51. Mamounas, E.P. (2001). Adjuvant exemestane therapy after 5 years of tamoxifen: Rationale for the NSABP B-33 trial. Oncology, 15(5, Suppl. 7), 35-39.
52. McCaskill-Stevens, W., Wilson, J., Bryant, J., Mamounas, E., Garvey, L., James, J., et al. (2004). Contralateral breast cancer and thromboembolic events in African American women treated with tamoxifen. Journal of the National Cancer Institute, 96(23), 1762-1769.
53. Michaud, L.B. (2005). Adjuvant use of aromatase inhibitors in postmenopausal women with breast cancer. American Journal of Health-System Pharmacy, 62(3), 266-273.
54. Miller, W.R. (2003). Aromatase inhibitors: Mechanism of action and role in the treatment of breast cancer. Seminars in Oncology, 30(4, Suppl. 14), 3-11.
55. Miller, W.R. (2004). Biological rationale for endocrine therapy in breast cancer. Best Practice and Research. Clinical Endocrinology and Metabolism, 18(1), 1-32.
56. Miller, W.R., & Dixon, J.M. (2000). Antiaromatase agents: Preclinical data and neoadjuvant therapy. Clinical Breast Cancer, 1(Suppl. 1), S9-S14.
57. Morales, L., Pans, S., Paridaens, R., Westhovens, R., Timmerman, D., Verhaeghe, J., et al. (2006). Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: Associated tenosynovial changes on magnetic resonance imaging. Breast Cancer Research and Treatment, 104(1), 87-91.
58. Morandi, P., Rouzier, R., Altundag, K., Buzdar, A.U., Theriault, R.L., & Hortobagyi, G. (2004). The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: The M.D. Anderson Cancer Center evidence-based approach. Cancer, 101(7), 1482-1489.
59. National Comprehensive Cancer Network. (2007). Clinical Practice Guidelines in Oncology™: Breast cancer [v.2.2007]. Retrieved. January 10, 2008, from http://www.nccn.org/professionals/physician-gls/PDF/breast.pdf
60. Novartis Pharmaceuticals. (2007). Femara® (letrozole tablets) [Package insert]. East Hanover, NJ: Author.
61. Palmieri, F.M., & Perez, E.A. (2003). Recent advances in adjuvant therapy for breast cancer. Seminars in Oncology Nursing, 19(4, Suppl. 2), 10-16.
62. Perez, E.A., Josse, R.C., Pritchard, K.I., Ingle, J.N., Martino, S., Findlay, B.P., et al. (2006). Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: A companion study to NCIC CTG MA. 17. Journal of Clinical Oncology, 24(22), 3629-3635.
63. Ring, A., & Dowsett, M. (2004). Mechanisms of tamoxifen resistance. Endocrine-Related Cancer, 11(4), 643-658.
64. Rosenzweig, M.Q. (2006). The oncology nurse practitioner: A unique provider for the follow-up for early-stage breast cancer. Journal of Clinical Oncology, 24(22), 3710-3711.
65. Shapiro, C.L. (2005). Aromatase inhibitors and bone loss: Risks in perspective [Letter to the editor]. Journal of Clinical Oncology, 23(22), 4847-4849.
66. Smith, I.E., & Dowsett, M. (2003). Aromatase inhibitors in breast cancer. New England Journal of Medicine, 348(24), 2431-2442.
67. Smith, I.E., Dowsett, M., Yap, Y.S., Walsh, G., Lonning, P.E., Santen, R.J., et al. (2006). Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: Caution and suggested guidelines. Journal of Clinical Oncology, 24(16), 2444-2447.
68. Viale, P.H. (2005). Aromatase inhibitor agents in breast cancer: Evolving practices in hormonal therapy treatment. Oncology Nursing Forum, 32(2), 343-353.
69. Whelan, T.J., Goss, P.E., Ingle, J.N., Pater, J.L., Tu, D., Pritchard, K., et al. (2005). Assessment of quality of life in MA. 17: A randomized, placebocontrolled trial of letrozole after 5 years of tamoxifen in postmenopausal women. Journal of Clinical Oncology, 23(28), 6931-6940.
70. Winer, E.P., Hudis, C., Burstein, H.J., Wolff, A.C., Pritchard, K.I., Ingle, J.N., et al. (2005). American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status Report 2004. Journal of Clinical Oncology, 23(3), 619-629.
71. Winters, L., Habin, K., & Gallagher, J. (2007). Aromatase inhibitors and musculoskeletal pain in patients with breast cancer. Clinical Journal of Oncology Nursing, 11(3), 433-439.